Emgality offers a specific 300 mg dose for patients with episodic cluster headache1

Redefine what’s possible for patients like Franka with Emgality 300 mg1
AGE: 40
CLUSTER HEADACHE FREQUENCY
- 1 to 4 times per day during active periods that last 7 weeks, followed by periods (≥3 months) of remission
MEDICAL HISTORY
- Diagnosed with episodic cluster headache 10 years ago
aHypothetical patient profile.
For the treatment of patients with episodic cluster headache,
Emgality 300 mg cut weekly cluster headache attacks in half or more for most patients1
Emgality 300 mg gives your patients a chance at ≥50% reduction in weekly cluster headache attack frequency1
- 71.4% of patients on Emgality 300 mg (N=49) experienced a ≥50% response from baseline vs 52.6% of patients on placebo (N=57) (p=0.046)
Emgality 300 mg reduced the number of weekly cluster headache attacks by an average of 8.7 vs 5.2 with placebo over Weeks 1 to 3 (baseline: 17.8 vs 17.3) (p=0.036)1b
bLeast-square (LS) means are presented.
INDICATION
Emgality is indicated for the treatment of episodic cluster headache in adults.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Review Episodic Cluster Headache study design
SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
Explore the efficacy for Emgality or download savings cardsc for eligible patients
cGovernmental beneficiaries excluded.
References:
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0085.